Machine learning models classify the likelihood of developing Alzheimer's.

Published Date: 05 Apr 2023

A new study suggests that once adults reach age 65, the cutoff age for Alzheimer's disease onset, the extent of their genetic risk may outweigh age as a predictor of whether they will experience the fatal brain disorder.

Read Full News

Latest News

NeuroVoices: Christina Briscoe, MD; Emily Spelbrink, MD, PhD, on Addressing Equity Gaps in Infantile Epileptic Spasms Syndrome Marco Meglio, Christina Briscoe, MD, Emily Spelbrink, MD, PhD

A pair of pediatric epileptologists highlight the systemic and patient level factors driving inequities in infantile epileptic spasms syndrome care and outline paths toward more equitable diagnosis and treatment.

GLP-1 Liraglutide Displays Effectiveness as Migraine Treatment in Early-Stage Study Louie Pasculli

In a pilot study, liraglutide, a drug used for diabetes and weight-loss, significantly reduced headache days in patients with obesity and chronic or high-frequency migraine, suggesting a potential new preventive therapy.

Fenfluramine Treatment Leads to Long-Term Improved Everyday Executive Functioning in Lennox-Gastaut Syndrome Marco Meglio

A recent analysis reveals fenfluramine's positive effects on executive functioning in adults with Lennox-Gastaut syndrome, independent of seizure reduction.

NeurologyLive®: Charting our 2026 Conference Coverage Louie Pasculli

Follow NeurologyLive's conference journey in 2026, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

AES Poster Shines Light on Positive Phase 3 GEMZ Study of Fenfluramine in CDKL5 Deficiency Disorder Marco Meglio

Fenfluramine shows significant seizure reduction in CDKL5 deficiency disorder, offering hope for families facing treatment-resistant epilepsy challenges.

Fenfluramine’s Safety Profile Consistent in Long-Term Extension Dravet and Lennox-Gastaut Syndrome Studies Isabella Ciccone, MPH

Final safety data from an open-label study presented at AES 2025 supported long-term fenfluramine use in pediatric and adult patients with Dravet syndrome or Lennox-Gastaut syndrome.

Todays Updates

Episode 158: Bexicaserin, the PACIFIC Trial, and Treating Developmental Epileptic Encephalopathies Marco Meglio, Johannes Streffer, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Johannes Streffer, MD. [LISTEN TIME: 14 minutes]

BMB-101 Heads for Registrational Trials Following Positive Phase 2 Data in Absence Seizures, Developmental Encephalopathies Marco Meglio

Bright Mind Biosciences reveals promising results for BMB-101 in treating drug-resistant seizures, paving the way for future clinical trials.

Key Neurology Trial Readouts to Watch in Early 2026 Isabella Ciccone, MPH

Review upcoming clinical trials with data readouts expected in the first half of 2026, providing updates relevant to ongoing research and clinical practice in neurology.

5 Rheumatology Headlines You Missed in December 2025

5 Rheumatology Headlines You Missed in December 2025

Diabetes, Anuria May Predict High Postvoid Residual After Kidney Transplantation

Diabetes, Anuria May Predict High Postvoid Residual After Kidney Transplantation

Todays Updates

Episode 158: Bexicaserin, the PACIFIC Trial, and Treating Developmental Epileptic Encephalopathies Marco Meglio, Johannes Streffer, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Johannes Streffer, MD. [LISTEN TIME: 14 minutes]

BMB-101 Heads for Registrational Trials Following Positive Phase 2 Data in Absence Seizures, Developmental Encephalopathies Marco Meglio

Bright Mind Biosciences reveals promising results for BMB-101 in treating drug-resistant seizures, paving the way for future clinical trials.

Key Neurology Trial Readouts to Watch in Early 2026 Isabella Ciccone, MPH

Review upcoming clinical trials with data readouts expected in the first half of 2026, providing updates relevant to ongoing research and clinical practice in neurology.

5 Rheumatology Headlines You Missed in December 2025

5 Rheumatology Headlines You Missed in December 2025

Diabetes, Anuria May Predict High Postvoid Residual After Kidney Transplantation

Diabetes, Anuria May Predict High Postvoid Residual After Kidney Transplantation

Latest News

A pair of pediatric epileptologists highlight the systemic and patient level factors driving inequities in infantile epileptic spasms syndrome care and outline paths toward more equitable diagnosis and treatment.

In a pilot study, liraglutide, a drug used for diabetes and weight-loss, significantly reduced headache days in patients with obesity and chronic or high-frequency migraine, suggesting a potential new preventive therapy.

A recent analysis reveals fenfluramine's positive effects on executive functioning in adults with Lennox-Gastaut syndrome, independent of seizure reduction.

Follow NeurologyLive's conference journey in 2026, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

Fenfluramine shows significant seizure reduction in CDKL5 deficiency disorder, offering hope for families facing treatment-resistant epilepsy challenges.

Final safety data from an open-label study presented at AES 2025 supported long-term fenfluramine use in pediatric and adult patients with Dravet syndrome or Lennox-Gastaut syndrome.

News All Time

Previewing Parkinson Disease Pipeline: Emerging Trials to Watch in 2026 Marco Meglio

As part of NeurologyLive®'s Year in Review, take a look at some of the top ongoing clinical trials in Parkinson disease that may impact care.

Previewing Expected FDA Decisions in Neurology for 2026 Marco Meglio

Explore anticipated FDA decisions on groundbreaking neurology drugs in 2026, shaping treatment options for various neurologic conditions.

NeurologyLive® Year in Review 2025: What Trials Could Reshape Alzheimer Care? Isabella Ciccone, MPH

As part of NeurologyLive®'s Year in Review, take a look at some of the top ongoing clinical trials in Alzheimer disease and dementia that may impact care.

NeurologyLive® Friday 5 — January 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 2, 2026.

Linking Exercise to Dopamine and Motor Performance in Parkinson Disease Marco Meglio

Margaret Rice, PhD, a professor in the Departments of Neurosurgery and Neuroscience at NYU Grossman School of Medicine, provided answers on recently published preclinical research relating aerobic exercise to dopamine release and coordination in PD.

NeurologyLive® Year in Review 2025: Top Interviews on the AI Takeover Isabella Ciccone, MPH

As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews on the latest advances and use of artificial intelligence in neurology care.

NeuroVoices: David A. Hafler, MD, FANA, on Understanding MS as an Autoimmune and Neurodegenerative Disease Isabella Ciccone, MPH, David A. Hafler, MD, FANA

At ECTRIMS 2025, the William S. and Lois Stiles Edgerly Professor of Neurology at Yale School of Medicine discussed evolving insights into the disease pathogenesis of multiple sclerosis.

NeurologyLive® Year in Review 2025: Top trending Migraine Trials NeurologyLive® Staff

As part of NeurologyLive®'s Year in Review 2025, we've compiled some of the top trending migraine trials.

NeurologyLive® Year in Review 2025: Spotlighting SAP Collaborations Isabella Ciccone, MPH

As part of NeurologyLive®'s Year in Review, take a look at our top collaborative interviews with the Strategic Alliance Partnership program in 2025.

NeurologyLive® Year in Review 2025: Most Impactful FDA Decisions Isabella Ciccone, MPH

These were the most impactful FDA approval stories that were part of our coverage in 2025, brought to you as part of NeurologyLive's Year in Review.

Phase 3 REVITALYZ Trial of Once-Nightly Sodium Oxybate in Idiopathic Hypersomnia Finishes Enrollment Marco Meglio

Avadel's REVITALYZ trial for Lumryz in idiopathic hypersomnia shows promise, potentially offering a new treatment option for this underserved condition.

NeurologyLive® Year in Review 2025: Conference Coverage Recap NeurologyLive® Staff

NeurologyLive® provided in-depth coverage of conferences in 2025, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

NeurologyLive® Brain Games: December 28, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on RBD as a prodromal marker for synucleinopathies!

Wnt/β-catenin in Multiple Sclerosis: A Nuanced Approach to Remyelination Kevin Chang, PharmD

In this Neuropathways piece, Kevin Chang, PharmD, explores the complexities of remyelination in multiple sclerosis and the potential of Wnt/β-catenin signaling as a therapeutic target.

This Week on NeurologyLive® — December 29, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

NeurologyLive® Friday 5 — December 26, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 26, 2025.

Recommended News For You

AI innovation unlocks non-surgical way to detect brain cancer spread

Survival is extended by a new treatment option for metastatic colorectal cancer.

Gene therapy and chemotherapy may be combined in novel ways to treat bone cancer.

Never in a million years did I think I'd have to limit my chemotherapy.

Why breast cancer survivors don't take their medicine, and what can be done about it.

Achieves a High Disease Control Rate in Head and Neck BCC with Vismodegib-RT Regimen.

Unraveling the role of exercise in cancer suppression

Recommended Articles For You

Uncovering Breast Cancer: The Power of Early Stage Ultrasound 

Adjuvant Atezolizumab in TNBC: What Recent Trials Reveal About Its Role 

Leukemia in Focus: Tools, Trials, and Therapy Strategies for Modern Medical Practice 

Polyposis Syndrome: Causes, Symptoms, and Treatment Options 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma

2.

Admissions, medical schools, costs, and eligibility requirements information for FNB Head and Neck Oncology.

3.

New research uncovers link between cancer pathway and blood-retina barrier function

4.

Lung cancer screening adherence rates decline annually after baseline screening

5.

Chromatin organization linked to p53 tumor suppression mechanism

1.

The Latest Research on Wiskott Aldrich Syndrome 

2.

The Role of the Oncology Pharmacist: From Treatment to Trials and Beyond

3.

The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring

4.

Paving the Path to Precision: A Review of TAR-200 in the Evolving Bladder Cancer Landscape

5.

Uncovering the Mystery of Burkitt's Lymphoma: A New Hope for Treatment

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion

2.

Efficient Management of First line ALK-rearranged NSCLC - Part VII

3.

Current Cancer Scenario in India- Importance of Genomic Testing & Advancement in Diagnosis and Treatment

4.

Efficient Management of First line ALK-rearranged NSCLC - Part V

5.

Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot